Jared Gollob
Vermögen: 6 Mio $ am 31.05.2026
Vermögen: 6 Mio $ am 31.05.2026
Dr. Jared Gollob, MD, is a Chief Medical Officer at Kymera Therapeutics, Inc. Dr. Gollob was previously employed as a Global VP-Medical Affairs & Clinical Development by Alnylam Pharmaceuticals, Inc. and a Director-Biologic Therapy Program by Duke University.
He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from The Trustees of Columbia University in The City of New York.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 71’359 ( 0.09% ) | 6 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.09.2007 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen